Le Lézard
Classified in: Covid-19 virus
Subject: Webcast

Agilent Technologies to Change Location of Annual Meeting


Agilent Technologies, Inc. (NYSE: A) today filed a supplement to its proxy statement with the Securities and Exchange Commission announcing a change of location for its previously adjourned annual meeting of stockholders. The meeting will be reconvened on Friday, April 17, 2020 at 8 a.m., Pacific Time. In light of public health considerations relating to the outbreak of COVID-19 and the need to comply with federal, state and local restrictions on gatherings and movement, the annual meeting will be held in a virtual meeting format only. Stockholders will not be able to attend the annual meeting physically.

For details on how to participate in the virtual annual meeting, please refer to the company's supplement to the proxy statement dated March 30, 2020.

About Agilent Technologies

Agilent Technologies Inc. (NYSE: A) is a global leader in life sciences, diagnostics and applied chemical markets. Now in its 20th year as an independent company delivering insight and innovation toward improving the quality of life, Agilent instruments, software, services, solutions and people provide trusted answers to customers' most challenging questions. The company generated revenue of $5.16 billion in fiscal 2019 and employs 16,300 people worldwide. Information about Agilent is available at www.agilent.com. To receive the latest Agilent news, subscribe to the Agilent Newsroom.

Follow Agilent on LinkedIn, Twitter, and Facebook.


These press releases may also interest you

at 10:15
Event Management Software Market worth $34.7 billion by 2029 - Exclusive Report by MarketsandMarketstm
More automation and artificial intelligence integration, improved capabilities for virtual and hybrid events, and an emphasis on data-driven insights and personalisation are what the Event Management Software Market will see in the future....

at 10:12
Acurx Pharmaceuticals Announces Presentation of Ibezapolostat Phase 2 Clinical Trial Results at upcoming ESCMID 2024 Scientific Conference
Acurx Pharmaceuticals, Inc. ("Acurx" or the "Company"), a clinical stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, announced today that results from the ibezapolstat Phase 2 clinical...

at 10:05
Gibson Dunn and Barrasso Usdin File Civil Rights Lawsuit to Secure Constitutional Rights of Young Woman Incarcerated for Over Six Months Despite Never Being Charged With a Crime
Gibson, Dunn & Crutcher LLP and Barrasso Usdin Kupperman Freeman & Sarver, LLC announce the filing of a civil rights action on behalf of Tayjha Alfred against Martin Bofill ("Bo") Duhé, the District Attorney for the 16th Judicial District of...

at 10:01
Control Valve Market worth $13.0 billion by 2029 - Exclusive Report by MarketsandMarketstm
The global Control Valve market is expected to grow from USD 10.0 billion in 2024 to USD 13.0 billion by 2029, registering a CAGR of 5.4% according to a new report by MarketsandMarketstm. The global market for control valves has experienced...

at 10:00
PER PERSON HEALTH CARE SPENDING EXCEEDED $6,700 IN 2022
A new report from the Health Care Cost Institute (HCCI) shows that, even with fluctuations in 2020 and 2021, per person health care spending grew from 2018 to 2022. Over the five years, average prices increased by 14% and utilization went up by about...

at 10:00
2024 ASCO | Mabwell to Present Clinical Data of 9MW2821 in Multiple Advanced Solid Tumor
Mabwell (688062.SH), an innovation-driven biopharmaceutical company with an entire industry chain, announced that the Phase I/II clinical study results of the novel Nectin-4-targeting ADC 9MW2821 for multiple advanced solid tumors will be presented...

More news about Covid-19 virus...


News published on and distributed by: